Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-09-08

Last Posted Date: 2013-01-08

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT00090909

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody

First Posted Date: 2004-09-08

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT00090896

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease

Phase 3

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-08-23

Last Posted Date: 2014-01-06

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00005024

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Other: Polyphenon E
Drug: erlotinib hydrochloride
Other: Erlotinib placebo

First Posted Date: 2004-08-05

Last Posted Date: 2020-07-31

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 17

Registration Number: NCT00088946

Locations: 🇺🇸
Santa Monica UCLA Medical Center, Santa Monica, California, United States
🇺🇸
Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

and more 2 locations

Irinotecan in Treating Patients With Esophageal or Stomach Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: irinotecan hydrochloride

First Posted Date: 2004-07-22

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 40

Registration Number: NCT00003748

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Cancer Care Associates Medical Group, Torrance, California, United States
🇺🇸
UCLA Cancer Center - Santa Clarita, Valencia, California, United States

and more 22 locations

Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: amifostine trihydrate
Drug: irinotecan hydrochloride

First Posted Date: 2004-07-21

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 23

Registration Number: NCT00003225

Locations: 🇺🇸
Wilshire Oncology Medical Group, Inc., Rancho Cucamonga, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-07-19

Last Posted Date: 2013-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00005996

Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-07-12

Last Posted Date: 2013-07-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00087061

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: docetaxel
Drug: erlotinib hydrochloride

First Posted Date: 2004-07-12

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT00087035

Locations: 🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸
University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States

Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Amifostine
Drug: DHAP

First Posted Date: 2004-06-16

Last Posted Date: 2012-10-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT00003143

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy